<DOC>
	<DOCNO>NCT01735838</DOCNO>
	<brief_summary>Summary Rationale : Cardiac resynchronisation therapy ( CRT ) biventricular pacemaker implantable cardiac defibrillator ( ICD ) proven valuable therapy select patient systolic heart failure , ameliorate morbidity mortality . However , current selection criterion implant technique , 20 30 % patient remain non-responders . Non-responders might due fail selection criterion methodology casu echocardiography . Moreover , definition response CRT unequivocal need simple reproducible measure response low inter- intra-observer variability . Primary objective : This study evaluate correlation intrathoracic blood volume ( ITBV ) measure contrast enhance ultrasound ( CEUS ) magnetic resonance imaging ( MRI ) , well feasibility use intrathoracic blood volume predictor response CRT . Study design : prospective nonrandomized pilot study Study population : patient heart failure New York Heart Association ( NYHA ) class III IV , leave ventricular ejection fraction equal le 35 % QRS-duration equal 0.12 second refer centre implantation CRT-P CRT-D device . Intervention : No specific intervention perform . Main study parameter : correlation intrathoracic bloodvolume measure CEUS MRI , correlation LVEF measure CEUS standard 2D ultrasound ( biplane method disc ) , change intrathoracic blood volume response CRT . Nature extent burden risk associate participation , benefit group relatedness : baseline clinical examination , laboratory analysis , cardiopulmonary exercise testing , echocardiography cardiac magnetic resonance imaging perform . All examination repeat 3-months follow-up except cardiac magnetic resonance imaging . All examination , except MRI , part standard workup hospital patient undergoing implantation CRT device . Data need purpose study , acquire offline image analysis dedicate software .</brief_summary>
	<brief_title>Intrathoracic Bloodvolume Measurement Contrast Enhanced Ultrasound : Validation Technique Evaluation Measurement Response Cardiac Resynchronization Therapy : Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Age ≥18y 2 . LVEF ≤35 % 3 . QRSduration ≥0.12 second 4 . NYHA functional class III IV despite optimal medical therapy define use angiotensinconverting enzyme inhibitor angiotensinII receptor blocker betablockers unless tolerate contraindicate 5. sinus rhythm atrial fibrillation 1. episode acute heart failure ≤3 month 2. change dosage betablockers , angiotensinconverting enzyme inhibitor angiotensinII receptor blocker ≤3 month 3. unstable angina pectoris , acute myocardial infarction , percutaneous intervention coronary bypass surgery ≤3 month 4. chronic atrial arrhythmia atrial fibrillation 5. mechanical biological valve prosthesis 6. atrial septal defect 7. righttoleft shunt 8. severe pulmonary hypertension ( systolic pulmonary artery pressure &gt; 90 mmHg ) 9. uncontrolled arterial hypertension 10. know allergy sulphur hexafluoride 11. endstage renal hepatic disease 12. inability provide write informed consent 13. pregnancy childbearing potential without use birthcontrol measurement 14. general contraindication magnetic resonance imaging</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>